Elaine McWhirter1, Ian Quirt2, Thomas Gajewski3, Gregory Pond4, Lisa Wang2, June Hui2, Amit Oza2. 1. Department of Medical Oncology, Juravinski Cancer Centre, Hamilton Health Sciences Centre, Hamilton, ON, Canada. emcwhirt@hhsc.ca. 2. Department of Medical Oncology, Princess Margaret Cancer Centre, Drug Development Program, Toronto, ON, Canada. 3. University of Chicago Medical Centre, Chicago, IL, USA. 4. Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada.
Abstract
PURPOSE: A two stage multi-institution Phase II study was undertaken by the Princess Margaret Hospital Consortium to evaluate the efficacy and toxicity of oral cediranib, an inhibitor of vascular endothelial growth factor receptors 1 and 2, in patients with previously untreated advanced malignant melanoma. PATIENTS AND METHODS: Between May 2006 and April 2008, 24 patients (median age 65 years) with advanced malignant melanoma were treated with oral cediranib. Cediranib was given on a continuous, oral once daily schedule of 45 mg, on a 28 day cycle. RESULTS: Of the 17 patients evaluable for response, there was stable disease in 8 patients, and progressive disease in 9 patients, with no objective responses seen. Only 2 patients had stable disease >/= 6 months, thus the study was terminated at the end of stage 1 accrual. The overall median survival was 9.9 months, and the median time to progression was 3.5 months. The most frequent non-hematologic adverse events were hypertension (78%), fatigue (69%), diarrhea (69%) and anorexia and nausea (each 57%). CONCLUSIONS: Although 2 patients had stable disease at 6 months, the short median time to progression and lack of any objective responses indicate that single agent cediranib at this dose and schedule is not sufficiently active to warrant study continuation.
PURPOSE: A two stage multi-institution Phase II study was undertaken by the Princess Margaret Hospital Consortium to evaluate the efficacy and toxicity of oral cediranib, an inhibitor of vascular endothelial growth factor receptors 1 and 2, in patients with previously untreated advanced malignant melanoma. PATIENTS AND METHODS: Between May 2006 and April 2008, 24 patients (median age 65 years) with advanced malignant melanoma were treated with oral cediranib. Cediranib was given on a continuous, oral once daily schedule of 45 mg, on a 28 day cycle. RESULTS: Of the 17 patients evaluable for response, there was stable disease in 8 patients, and progressive disease in 9 patients, with no objective responses seen. Only 2 patients had stable disease >/= 6 months, thus the study was terminated at the end of stage 1 accrual. The overall median survival was 9.9 months, and the median time to progression was 3.5 months. The most frequent non-hematologic adverse events were hypertension (78%), fatigue (69%), diarrhea (69%) and anorexia and nausea (each 57%). CONCLUSIONS: Although 2 patients had stable disease at 6 months, the short median time to progression and lack of any objective responses indicate that single agent cediranib at this dose and schedule is not sufficiently active to warrant study continuation.
Entities:
Keywords:
Cediranib; First line therapy; Metastatic melanoma; Phase II trial; Vascular endothelial growth factor (VEGF)
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: R Goodwin; K Ding; L Seymour; A LeMaître; A Arnold; F A Shepherd; M Dediu; T Ciuleanu; D Fenton; M Zukin; D Walde; F Laberge; M Vincent; P M Ellis; S A Laurie Journal: Ann Oncol Date: 2010-04-28 Impact factor: 32.976
Authors: Linda L Garland; Kari Chansky; Antoinette J Wozniak; Anne S Tsao; Shirish M Gadgeel; Claire F Verschraegen; Marco A Dasilva; Mary Redman; David R Gandara Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Keith T Flaherty; Sandra J Lee; Fengmin Zhao; Lynn M Schuchter; Lawrence Flaherty; Richard Kefford; Michael B Atkins; Philip Leming; John M Kirkwood Journal: J Clin Oncol Date: 2012-12-17 Impact factor: 44.544
Authors: Domingo G Perez; Vera J Suman; Tom R Fitch; Thomas Amatruda; Roscoe F Morton; Shamim Z Jilani; Costas L Constantinou; James R Egner; Lisa A Kottschade; Svetomir N Markovic Journal: Cancer Date: 2009-01-01 Impact factor: 6.860
Authors: Ursula A Matulonis; Suzanne Berlin; Percy Ivy; Karin Tyburski; Carolyn Krasner; Corrine Zarwan; Anna Berkenblit; Susana Campos; Neil Horowitz; Stephen A Cannistra; Hang Lee; Julie Lee; Maria Roche; Margaret Hill; Christin Whalen; Laura Sullivan; Chau Tran; Benjamin D Humphreys; Richard T Penson Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Kimberly A Varker; Jennifer E Biber; Cheryl Kefauver; Rhonda Jensen; Amy Lehman; Donn Young; Haifeng Wu; Gregory B Lesinski; Kari Kendra; Helen X Chen; Michael J Walker; William E Carson Journal: Ann Surg Oncol Date: 2007-05-30 Impact factor: 5.344
Authors: Claire L Mitchell; J P B O'Connor; C Roberts; Y Watson; A Jackson; S Cheung; J Evans; J Spicer; A Harris; C Kelly; S Rudman; M Middleton; A Fielding; J Tessier; H Young; G J M Parker; G C Jayson Journal: Cancer Chemother Pharmacol Date: 2010-12-01 Impact factor: 3.333
Authors: Anna Piotrowska; Fernando Pereira Beserra; Justyna Marta Wierzbicka; Joanna Irena Nowak; Michał Aleksander Żmijewski Journal: Front Oncol Date: 2021-12-24 Impact factor: 6.244